January 8, 2024 by Sheila Arquette
Health care outlook 2024: Sheila Arquette President and CEO, National Association of Specialty Pharmacy
January 8, 2024, Opinion, Pharmacy
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. Specialty pharmacy continues to be dynamic, demanding and disruptive. As the market continues to demand specialization in drug distribution and
January 10, 2023 by Sheila Arquette
Sheila Arquette is president and chief executive officer of the National Association of Specialty Pharmacy.
January 9, 2023, Opinion
Specialty pharmacy continues to be dynamic, demanding and disruptive, undergoing rapid and dramatic change. Specialty pharmacies connect patients diagnosed with life-altering and often life-threatening complex health conditions, including cancer, rheumatoid arthritis, multiple sclerosis, cystic fibrosis, hemophilia, rare and orphan diseases, and organ transplantation, with the medications prescribed for their conditions. The expert services that specialty
January 10, 2022 by Sheila Arquette
Sheila Arquette NASP
January 10, 2022, Opinion, Pharmacy
Specialty pharmacies support patients diagnosed with life-altering and oftentimes life threatening complex health conditions, including cancer, rheumatoid arthritis, multiple sclerosis, cystic fibrosis, hemophilia, rare and orphan diseases and organ transplantation. The National Association of Specialty Pharmacy is a nonprofit trade organization and the only national association representing all specialty pharmacy industry stakeholders. The mission of
January 5, 2021 by Sheila Arquette
Sheila Arquette is the executive director at the National Association of Specialty Pharmacy.
January 4, 2021, Pharmacy
The COVID-19 pandemic has altered life as we know it and impacted each of us in a very personal way. The scale and magnitude of the pandemic brought sudden and unexpected challenges and opportunities for all specialty pharmacy stakeholders. As we look to the future, we must consider the impacts the COVID-19 pandemic has had
January 17, 2020 by Sheila Arquette
National Association of Specialty Pharmacy, Sheila Arquette
January 6, 2020, Opinion
In its infancy, specialty pharmacy truly was a niche industry serving a limited number of patients with a small number of high-cost, low-volume, chronic or complex conditions, such as hemophilia and Gaucher’s disease. Specialty pharmacies came into existence as a result of unmet needs. As more drugs derived from biotechnology with higher-than-average prescription prices became